Migraine Briefs

Key clinical point: DFN-15- an oral, ready-made liquid solution of a selective cyclo-oxygenase-2 inhibitor celecoxib, was superior to placebo for acute treatment of a migraine attack of any pain intensity, along with a favorable safety and tolerability profile.

Major finding: Percentage of patients with freedom from pain (46.2% vs. 31.1%; P less than.001) and freedom from the most bothersome symptom (63.4% vs. 50.0%; P = .010) at 2 hours after dose was significantly higher for DFN-15 vs. placebo. No serious treatment-emergent adverse events or those leading to study drug termination were reported.

Study details: Data come from the second phase of a 2-phase, double-blind, multicenter trial, which re-randomized 535 patients with migraine to placebo or DFN-15 group.

Disclosures: This study was supported and funded by Dr. Reddy’s Laboratories group of companies, Princeton, NJ 08540, USA. The authors declared receiving funding, honoraria, and consulting from various sources. S Munjal reported being an employee and owning stocks and C Iaconangelo declared being a paid consultant of Dr. Reddy’s Laboratories.

Source: Lipton RB et al. J Pain Res. 2021 Feb 25. doi: 10.2147/JPR.S287571.

Key clinical point: DFN-15- an oral, ready-made liquid solution of a selective cyclo-oxygenase-2 inhibitor celecoxib, was superior to placebo for acute treatment of a migraine attack of any pain intensity, along with a favorable safety and tolerability profile.

Major finding: Percentage of patients with freedom from pain (46.2% vs. 31.1%; P less than.001) and freedom from the most bothersome symptom (63.4% vs. 50.0%; P = .010) at 2 hours after dose was significantly higher for DFN-15 vs. placebo. No serious treatment-emergent adverse events or those leading to study drug termination were reported.

Study details: Data come from the second phase of a 2-phase, double-blind, multicenter trial, which re-randomized 535 patients with migraine to placebo or DFN-15 group.

Disclosures: This study was supported and funded by Dr. Reddy’s Laboratories group of companies, Princeton, NJ 08540, USA. The authors declared receiving funding, honoraria, and consulting from various sources. S Munjal reported being an employee and owning stocks and C Iaconangelo declared being a paid consultant of Dr. Reddy’s Laboratories.

Source: Lipton RB et al. J Pain Res. 2021 Feb 25. doi: 10.2147/JPR.S287571.

Key clinical point: DFN-15- an oral, ready-made liquid solution of a selective cyclo-oxygenase-2 inhibitor celecoxib, was superior to placebo for acute treatment of a migraine attack of any pain intensity, along with a favorable safety and tolerability profile.

Major finding: Percentage of patients with freedom from pain (46.2% vs. 31.1%; P less than.001) and freedom from the most bothersome symptom (63.4% vs. 50.0%; P = .010) at 2 hours after dose was significantly higher for DFN-15 vs. placebo. No serious treatment-emergent adverse events or those leading to study drug termination were reported.

Study details: Data come from the second phase of a 2-phase, double-blind, multicenter trial, which re-randomized 535 patients with migraine to placebo or DFN-15 group.

Disclosures: This study was supported and funded by Dr. Reddy’s Laboratories group of companies, Princeton, NJ 08540, USA. The authors declared receiving funding, honoraria, and consulting from various sources. S Munjal reported being an employee and owning stocks and C Iaconangelo declared being a paid consultant of Dr. Reddy’s Laboratories.

Source: Lipton RB et al. J Pain Res. 2021 Feb 25. doi: 10.2147/JPR.S287571.

Key clinical point: Triptan historical responder status had no significant impact on the treatment effects of ubrogepant in patients with a history of migraine.

Major finding: Historical triptan responder status had no significant impact on the efficacy of ubrogepant for pain freedom (P_interaction based on odds ratio [OR] = .290) and absence of migraine-associated symptom (P_interaction based on OR = .705). The incidence of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs was not significantly different across historical triptan experience subgroups.

Study details: This was a post hoc analysis of pooled data from ACHIEVE I and II phase 3 trials involving 1,799 adults with a history of migraine with/without aura randomly allocated to either placebo or ubrogepant to treat a single attack. Based on previous experience with triptans, participants were categorized as responders, insufficient responders, and naïve.

Disclosures: The study was sponsored by Allergan. Some authors including the lead author declared receiving grants and personal fees; being consultant, speaker, or contributing author; or being on advisory boards for various sources including AbbVie. Some authors declared being current/former employees and/or holding stocks at AbbVie.

Source: Blumenfeld AM et al. Headache. 2021 Mar 22. doi: 10.1111/head.14089.

Key clinical point: Triptan historical responder status had no significant impact on the treatment effects of ubrogepant in patients with a history of migraine.

Major finding: Historical triptan responder status had no significant impact on the efficacy of ubrogepant for pain freedom (P_interaction based on odds ratio [OR] = .290) and absence of migraine-associated symptom (P_interaction based on OR = .705). The incidence of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs was not significantly different across historical triptan experience subgroups.

Study details: This was a post hoc analysis of pooled data from ACHIEVE I and II phase 3 trials involving 1,799 adults with a history of migraine with/without aura randomly allocated to either placebo or ubrogepant to treat a single attack. Based on previous experience with triptans, participants were categorized as responders, insufficient responders, and naïve.

Disclosures: The study was sponsored by Allergan. Some authors including the lead author declared receiving grants and personal fees; being consultant, speaker, or contributing author; or being on advisory boards for various sources including AbbVie. Some authors declared being current/former employees and/or holding stocks at AbbVie.

Source: Blumenfeld AM et al. Headache. 2021 Mar 22. doi: 10.1111/head.14089.

Key clinical point: Triptan historical responder status had no significant impact on the treatment effects of ubrogepant in patients with a history of migraine.

Major finding: Historical triptan responder status had no significant impact on the efficacy of ubrogepant for pain freedom (P_interaction based on odds ratio [OR] = .290) and absence of migraine-associated symptom (P_interaction based on OR = .705). The incidence of treatment-emergent adverse events (TEAEs) and treatment-related TEAEs was not significantly different across historical triptan experience subgroups.

Study details: This was a post hoc analysis of pooled data from ACHIEVE I and II phase 3 trials involving 1,799 adults with a history of migraine with/without aura randomly allocated to either placebo or ubrogepant to treat a single attack. Based on previous experience with triptans, participants were categorized as responders, insufficient responders, and naïve.

Disclosures: The study was sponsored by Allergan. Some authors including the lead author declared receiving grants and personal fees; being consultant, speaker, or contributing author; or being on advisory boards for various sources including AbbVie. Some authors declared being current/former employees and/or holding stocks at AbbVie.

Source: Blumenfeld AM et al. Headache. 2021 Mar 22. doi: 10.1111/head.14089.

Key clinical point: Patients with migraine respond to preventive treatment with monoclonal antibodies targeting calcitonin gene-related peptide (anti-CGRP mAbs) irrespective of their previous failure or partial response to onabotulinumtoxinA.

Major finding: A response of 50% or higher improvement in headache (P = .395) or migraine (P = .408) frequency was not significantly different in partial or complete nonresponders to onabotulinumtoxinA.

Study details: This was a real-world prospective observational study including 155 patients with migraine who initiated preventive treatment with anti-CGRP mAbs and were partial or nonresponders to onabotulinumtoxinA.

Disclosures: The authors declared receiving no financial support for the research, authorship, and/or publication of this article. The authors report no conflicts of interest in relation with this article.

Source: Alpuente A et al. Eur J Neurol. 2021 Mar 17. doi: 10.1111/ene.14828.

Key clinical point: Patients with migraine respond to preventive treatment with monoclonal antibodies targeting calcitonin gene-related peptide (anti-CGRP mAbs) irrespective of their previous failure or partial response to onabotulinumtoxinA.

Major finding: A response of 50% or higher improvement in headache (P = .395) or migraine (P = .408) frequency was not significantly different in partial or complete nonresponders to onabotulinumtoxinA.

Study details: This was a real-world prospective observational study including 155 patients with migraine who initiated preventive treatment with anti-CGRP mAbs and were partial or nonresponders to onabotulinumtoxinA.

Disclosures: The authors declared receiving no financial support for the research, authorship, and/or publication of this article. The authors report no conflicts of interest in relation with this article.

Source: Alpuente A et al. Eur J Neurol. 2021 Mar 17. doi: 10.1111/ene.14828.

Key clinical point: Patients with migraine respond to preventive treatment with monoclonal antibodies targeting calcitonin gene-related peptide (anti-CGRP mAbs) irrespective of their previous failure or partial response to onabotulinumtoxinA.

Major finding: A response of 50% or higher improvement in headache (P = .395) or migraine (P = .408) frequency was not significantly different in partial or complete nonresponders to onabotulinumtoxinA.

Study details: This was a real-world prospective observational study including 155 patients with migraine who initiated preventive treatment with anti-CGRP mAbs and were partial or nonresponders to onabotulinumtoxinA.

Disclosures: The authors declared receiving no financial support for the research, authorship, and/or publication of this article. The authors report no conflicts of interest in relation with this article.

Source: Alpuente A et al. Eur J Neurol. 2021 Mar 17. doi: 10.1111/ene.14828.

Key clinical point: Women vs. men with migraine had a higher frequency of self-reported neck pain and higher prevalence and severity of cutaneous allodynia (CA).

Major finding: Women vs. men showed higher prevalence of self-reported neck pain (73.33% vs. 43.33%; P = .04), CA (P = .001), and 4 times higher risk of having severe CA (P = .007).

Study details: Findings are from a cross-sectional study of 30 men and 30 women with migraine.

Disclosures: The study was supported by a grant from the Fundação de Amparo à Pesquisa do Estado de São Paulo to NDS Xavier. No other conflicts of interest were reported.

Source: Xavier NDS et al. Pain Med. 2021 Mar 19. doi: 10.1093/pm/pnab106.

Key clinical point: Women vs. men with migraine had a higher frequency of self-reported neck pain and higher prevalence and severity of cutaneous allodynia (CA).

Major finding: Women vs. men showed higher prevalence of self-reported neck pain (73.33% vs. 43.33%; P = .04), CA (P = .001), and 4 times higher risk of having severe CA (P = .007).

Study details: Findings are from a cross-sectional study of 30 men and 30 women with migraine.

Disclosures: The study was supported by a grant from the Fundação de Amparo à Pesquisa do Estado de São Paulo to NDS Xavier. No other conflicts of interest were reported.

Source: Xavier NDS et al. Pain Med. 2021 Mar 19. doi: 10.1093/pm/pnab106.

Key clinical point: Women vs. men with migraine had a higher frequency of self-reported neck pain and higher prevalence and severity of cutaneous allodynia (CA).

Major finding: Women vs. men showed higher prevalence of self-reported neck pain (73.33% vs. 43.33%; P = .04), CA (P = .001), and 4 times higher risk of having severe CA (P = .007).

Study details: Findings are from a cross-sectional study of 30 men and 30 women with migraine.

Disclosures: The study was supported by a grant from the Fundação de Amparo à Pesquisa do Estado de São Paulo to NDS Xavier. No other conflicts of interest were reported.

Source: Xavier NDS et al. Pain Med. 2021 Mar 19. doi: 10.1093/pm/pnab106.

Key clinical point: People with migraine may experience a wide range of comorbidities and co-occurring conditions, which should be managed effectively.

Major finding: Patients with vs. without migraine were 3 times more likely to experience insomnia (adjusted odds ratio [aOR], 3.79; 95% confidence interval, [95% CI], 3.6-4.0), depression (aOR, 3.18; 95% CI, 3.0-3.3), anxiety (aOR, 3.18; 95% CI, 3.0-3.3), and gastric ulcer/gastrointestinal bleeding (aOR, 3.11; 95% CI, 2.8-3.5).

Study details: Data come from the prospective, web-based Migraine in America Symptoms and Treatment survey involving adults with (n=15,133) and without migraine (n=77,453).

Disclosures: The study was funded and sponsored by Dr. Reddy’s Laboratories group of companies, Princeton, USA. The lead author along with others declared receiving grant support and/or honoraria from various sources. S Munjal and P Singh declared being employees while RB Lipton, DC Buse, ML Reed, TJ Schwedt, and DW Dodick reported being consultants at Dr. Reddy’s Laboratories.

Source: Buse DC et al. J Headache Pain. 2020 Mar 2. doi: 10.1186/s10194-020-1084-y.

Key clinical point: People with migraine may experience a wide range of comorbidities and co-occurring conditions, which should be managed effectively.

Major finding: Patients with vs. without migraine were 3 times more likely to experience insomnia (adjusted odds ratio [aOR], 3.79; 95% confidence interval, [95% CI], 3.6-4.0), depression (aOR, 3.18; 95% CI, 3.0-3.3), anxiety (aOR, 3.18; 95% CI, 3.0-3.3), and gastric ulcer/gastrointestinal bleeding (aOR, 3.11; 95% CI, 2.8-3.5).

Study details: Data come from the prospective, web-based Migraine in America Symptoms and Treatment survey involving adults with (n=15,133) and without migraine (n=77,453).

Disclosures: The study was funded and sponsored by Dr. Reddy’s Laboratories group of companies, Princeton, USA. The lead author along with others declared receiving grant support and/or honoraria from various sources. S Munjal and P Singh declared being employees while RB Lipton, DC Buse, ML Reed, TJ Schwedt, and DW Dodick reported being consultants at Dr. Reddy’s Laboratories.

Source: Buse DC et al. J Headache Pain. 2020 Mar 2. doi: 10.1186/s10194-020-1084-y.

Key clinical point: People with migraine may experience a wide range of comorbidities and co-occurring conditions, which should be managed effectively.

Major finding: Patients with vs. without migraine were 3 times more likely to experience insomnia (adjusted odds ratio [aOR], 3.79; 95% confidence interval, [95% CI], 3.6-4.0), depression (aOR, 3.18; 95% CI, 3.0-3.3), anxiety (aOR, 3.18; 95% CI, 3.0-3.3), and gastric ulcer/gastrointestinal bleeding (aOR, 3.11; 95% CI, 2.8-3.5).

Study details: Data come from the prospective, web-based Migraine in America Symptoms and Treatment survey involving adults with (n=15,133) and without migraine (n=77,453).

Disclosures: The study was funded and sponsored by Dr. Reddy’s Laboratories group of companies, Princeton, USA. The lead author along with others declared receiving grant support and/or honoraria from various sources. S Munjal and P Singh declared being employees while RB Lipton, DC Buse, ML Reed, TJ Schwedt, and DW Dodick reported being consultants at Dr. Reddy’s Laboratories.

Source: Buse DC et al. J Headache Pain. 2020 Mar 2. doi: 10.1186/s10194-020-1084-y.

Key clinical point: Addition of a calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (mAbs) in patients with chronic migraine (CM) receiving onabotulinumtoxinA (onabot) resulted in further reductions in monthly headache days (MHDs) without major tolerability issues.

Major finding: Patients reported an average decrease of 10.9 MHDs (P less than .001) after onabot treatment and a further decrease of 5.7 MHDs (P less than .001) after addition of CGRP-targeted mAbs resulting in a total decrease of 16.6 MHDs (P less than .001) with combined therapy. No serious adverse events were reported.

Study details: The data come from a retrospective review of 153 patients with CM receiving onabot and subsequently prescribed CGRP-targeted mAbs.

Disclosures: The study did not receive any funding. The lead author F Cohen reported no conflicts of interest. The other authors declared receiving honoraria and research support from various sources and serving as consultant and/or advisory board member for various pharmaceutical companies.

Source: Cohen F et al. Pain Med. 2021 Mar 8. doi: 10.1093/pm/pnab093.

Key clinical point: Addition of a calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (mAbs) in patients with chronic migraine (CM) receiving onabotulinumtoxinA (onabot) resulted in further reductions in monthly headache days (MHDs) without major tolerability issues.

Major finding: Patients reported an average decrease of 10.9 MHDs (P less than .001) after onabot treatment and a further decrease of 5.7 MHDs (P less than .001) after addition of CGRP-targeted mAbs resulting in a total decrease of 16.6 MHDs (P less than .001) with combined therapy. No serious adverse events were reported.

Study details: The data come from a retrospective review of 153 patients with CM receiving onabot and subsequently prescribed CGRP-targeted mAbs.

Disclosures: The study did not receive any funding. The lead author F Cohen reported no conflicts of interest. The other authors declared receiving honoraria and research support from various sources and serving as consultant and/or advisory board member for various pharmaceutical companies.

Source: Cohen F et al. Pain Med. 2021 Mar 8. doi: 10.1093/pm/pnab093.

Key clinical point: Addition of a calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies (mAbs) in patients with chronic migraine (CM) receiving onabotulinumtoxinA (onabot) resulted in further reductions in monthly headache days (MHDs) without major tolerability issues.

Major finding: Patients reported an average decrease of 10.9 MHDs (P less than .001) after onabot treatment and a further decrease of 5.7 MHDs (P less than .001) after addition of CGRP-targeted mAbs resulting in a total decrease of 16.6 MHDs (P less than .001) with combined therapy. No serious adverse events were reported.

Study details: The data come from a retrospective review of 153 patients with CM receiving onabot and subsequently prescribed CGRP-targeted mAbs.

Disclosures: The study did not receive any funding. The lead author F Cohen reported no conflicts of interest. The other authors declared receiving honoraria and research support from various sources and serving as consultant and/or advisory board member for various pharmaceutical companies.

Source: Cohen F et al. Pain Med. 2021 Mar 8. doi: 10.1093/pm/pnab093.

Key clinical point: Intravenous eptinezumab demonstrated a favorable safety profile in patients with chronic migraine (CM).

Major finding: Overall, 71.1% of patients experienced 1 or more treatment-emergent adverse events (TEAEs) during the entire 2 years of study duration with majority (95.6%) being mild or moderate. TEAEs leading to drug discontinuation or withdrawal were observed in only 7.8% and 6.3% of patients, respectively. Incidence of serious TEAEs and drug-related AEs was low.

Study details: PREVAIL, an open-label phase 3 trial, included 128 adults with CM who received at least 1 dose of eptinezumab (300 mg) every 12 weeks for up to 8 doses.

Disclosures: This study was funded by H. Lundbeck A/S, Copenhagen, Denmark. D Kudrow reported receiving grant support from, being on advisory board, and/or being speaker for multiple sources. Some of the authors reported being current/former full-time employees at Lundbeck Seattle BioPharmaceuticals or Alder Biopharmaceuticals (CKA Lundbeck Seattle Biopharmaceuticals, Inc).

Source: Kudrow D et al. BMC Neurol. 2021 Mar 19. doi: 10.1186/s12883-021-02123-w.

Key clinical point: Intravenous eptinezumab demonstrated a favorable safety profile in patients with chronic migraine (CM).

Major finding: Overall, 71.1% of patients experienced 1 or more treatment-emergent adverse events (TEAEs) during the entire 2 years of study duration with majority (95.6%) being mild or moderate. TEAEs leading to drug discontinuation or withdrawal were observed in only 7.8% and 6.3% of patients, respectively. Incidence of serious TEAEs and drug-related AEs was low.

Study details: PREVAIL, an open-label phase 3 trial, included 128 adults with CM who received at least 1 dose of eptinezumab (300 mg) every 12 weeks for up to 8 doses.

Disclosures: This study was funded by H. Lundbeck A/S, Copenhagen, Denmark. D Kudrow reported receiving grant support from, being on advisory board, and/or being speaker for multiple sources. Some of the authors reported being current/former full-time employees at Lundbeck Seattle BioPharmaceuticals or Alder Biopharmaceuticals (CKA Lundbeck Seattle Biopharmaceuticals, Inc).

Source: Kudrow D et al. BMC Neurol. 2021 Mar 19. doi: 10.1186/s12883-021-02123-w.

Key clinical point: Intravenous eptinezumab demonstrated a favorable safety profile in patients with chronic migraine (CM).

Major finding: Overall, 71.1% of patients experienced 1 or more treatment-emergent adverse events (TEAEs) during the entire 2 years of study duration with majority (95.6%) being mild or moderate. TEAEs leading to drug discontinuation or withdrawal were observed in only 7.8% and 6.3% of patients, respectively. Incidence of serious TEAEs and drug-related AEs was low.

Study details: PREVAIL, an open-label phase 3 trial, included 128 adults with CM who received at least 1 dose of eptinezumab (300 mg) every 12 weeks for up to 8 doses.

Disclosures: This study was funded by H. Lundbeck A/S, Copenhagen, Denmark. D Kudrow reported receiving grant support from, being on advisory board, and/or being speaker for multiple sources. Some of the authors reported being current/former full-time employees at Lundbeck Seattle BioPharmaceuticals or Alder Biopharmaceuticals (CKA Lundbeck Seattle Biopharmaceuticals, Inc).

Source: Kudrow D et al. BMC Neurol. 2021 Mar 19. doi: 10.1186/s12883-021-02123-w.

Key clinical point: Over half of the patients with migraine who underwent bariatric surgery experienced migraine remission following surgery, with likelihood of remission being higher after Roux-en-Y gastric bypass (RYGB) than after vertical sleeve gastrectomy (VSG).

Major finding: Remission of migraine was observed in 55.4% of patients who underwent surgery. Likelihood of migraine remission was higher with RYGB vs. VSG (adjusted relative rate, 1.11; 95% confidence interval, 1.05-1.17).

Study details: The data come from a retrospective analysis of 1,680 patients with chronic migraine who underwent bariatric surgery (RYGB, n=742; VSG, n=938) between 2010 and 2017.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Nudotor R et al. Obes Surg. 2021 Feb 11. doi: 10.1007/s11695-020-05204-w.

Key clinical point: Over half of the patients with migraine who underwent bariatric surgery experienced migraine remission following surgery, with likelihood of remission being higher after Roux-en-Y gastric bypass (RYGB) than after vertical sleeve gastrectomy (VSG).

Major finding: Remission of migraine was observed in 55.4% of patients who underwent surgery. Likelihood of migraine remission was higher with RYGB vs. VSG (adjusted relative rate, 1.11; 95% confidence interval, 1.05-1.17).

Study details: The data come from a retrospective analysis of 1,680 patients with chronic migraine who underwent bariatric surgery (RYGB, n=742; VSG, n=938) between 2010 and 2017.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Nudotor R et al. Obes Surg. 2021 Feb 11. doi: 10.1007/s11695-020-05204-w.

Key clinical point: Over half of the patients with migraine who underwent bariatric surgery experienced migraine remission following surgery, with likelihood of remission being higher after Roux-en-Y gastric bypass (RYGB) than after vertical sleeve gastrectomy (VSG).

Major finding: Remission of migraine was observed in 55.4% of patients who underwent surgery. Likelihood of migraine remission was higher with RYGB vs. VSG (adjusted relative rate, 1.11; 95% confidence interval, 1.05-1.17).

Study details: The data come from a retrospective analysis of 1,680 patients with chronic migraine who underwent bariatric surgery (RYGB, n=742; VSG, n=938) between 2010 and 2017.

Disclosures: No source of funding was declared. The authors declared no conflicts of interest.

Source: Nudotor R et al. Obes Surg. 2021 Feb 11. doi: 10.1007/s11695-020-05204-w.

Key clinical point: In real-world settings, candesartan showed benefit as a preventive treatment for migraine with a 50% responder rate, similar to that observed in previous trials.

Major finding: Candesartan significantly reduced the number of headache days per month compared with baseline at weeks 8-12 (−4.3 days) and 20-24 (−4.7 days; both P less than .001). By weeks 8-12 and 20-24, 50% response was observed in 32.5% and 31.7% of patients, respectively. Common adverse events were light-headedness (5.0%), hypotension (4.2%), sleepiness (0.8%), and asthenia (0.8%).

Study details: The data come from a retrospective cohort study of 120 patients with chronic or episodic migraine who received candesartan between April 2008 and February 2019.

Disclosures: The study was a dissertation project supported by Junta de Castilla y León (Spain) and the European Social Fund. The authors declared no conflicts of interest.

Source: Sánchez-Rodríguez C et al. Sci Rep. 2021 Feb 15. doi: 10.1038/s41598-021-83508-2.

Key clinical point: In real-world settings, candesartan showed benefit as a preventive treatment for migraine with a 50% responder rate, similar to that observed in previous trials.

Major finding: Candesartan significantly reduced the number of headache days per month compared with baseline at weeks 8-12 (−4.3 days) and 20-24 (−4.7 days; both P less than .001). By weeks 8-12 and 20-24, 50% response was observed in 32.5% and 31.7% of patients, respectively. Common adverse events were light-headedness (5.0%), hypotension (4.2%), sleepiness (0.8%), and asthenia (0.8%).

Study details: The data come from a retrospective cohort study of 120 patients with chronic or episodic migraine who received candesartan between April 2008 and February 2019.

Disclosures: The study was a dissertation project supported by Junta de Castilla y León (Spain) and the European Social Fund. The authors declared no conflicts of interest.

Source: Sánchez-Rodríguez C et al. Sci Rep. 2021 Feb 15. doi: 10.1038/s41598-021-83508-2.

Key clinical point: In real-world settings, candesartan showed benefit as a preventive treatment for migraine with a 50% responder rate, similar to that observed in previous trials.

Major finding: Candesartan significantly reduced the number of headache days per month compared with baseline at weeks 8-12 (−4.3 days) and 20-24 (−4.7 days; both P less than .001). By weeks 8-12 and 20-24, 50% response was observed in 32.5% and 31.7% of patients, respectively. Common adverse events were light-headedness (5.0%), hypotension (4.2%), sleepiness (0.8%), and asthenia (0.8%).

Study details: The data come from a retrospective cohort study of 120 patients with chronic or episodic migraine who received candesartan between April 2008 and February 2019.

Disclosures: The study was a dissertation project supported by Junta de Castilla y León (Spain) and the European Social Fund. The authors declared no conflicts of interest.

Source: Sánchez-Rodríguez C et al. Sci Rep. 2021 Feb 15. doi: 10.1038/s41598-021-83508-2.

Key clinical point: The prevalence of cutaneous allodynia (CA) was comparable among patients with probable migraine (PM) and migraine. Anxiety, depression, and headache frequency/intensity were significant factors for CA in PM.

Major finding: Participants with PM (n=289) and migraine (n=125) showed a similar prevalence of CA (14.5% vs. 16.0%; P = .701). The factors significantly associated with CA in PM were moderate (adjusted odds ratio [aOR], 2.4; 95% confidence interval [CI], 1.1-5.4) and severe (aOR, 4.0; 95% CI, 1.1-13.9) headache intensity, anxiety (aOR, 5.2; 95% CI, 1.7-16.3), and depression (aOR, 3.3; 95% CI, 1.5-7.6).

Study details: The data come from the Korean Sleep-Headache Study, a population-based, cross-sectional survey on headache and sleep involving 2,501 participants.

Disclosures: This study was supported by the National Research Foundation of Korea grant from the Korean government. S‐J Cho and M K Chu were site investigators for a multicenter trial sponsored by Otsuka Korea, Eli Lilly and Co., and others. S-J Cho and MK Chu have worked as advisory members for Teva and have declared research support/lecture honoraria/grants from different sources. The other authors declared no conflicts of interest.

Source: Han SM et al. Sci Rep. 2021 Jan 28. doi: 10.1038/s41598-021-82080-z.

Key clinical point: The prevalence of cutaneous allodynia (CA) was comparable among patients with probable migraine (PM) and migraine. Anxiety, depression, and headache frequency/intensity were significant factors for CA in PM.

Major finding: Participants with PM (n=289) and migraine (n=125) showed a similar prevalence of CA (14.5% vs. 16.0%; P = .701). The factors significantly associated with CA in PM were moderate (adjusted odds ratio [aOR], 2.4; 95% confidence interval [CI], 1.1-5.4) and severe (aOR, 4.0; 95% CI, 1.1-13.9) headache intensity, anxiety (aOR, 5.2; 95% CI, 1.7-16.3), and depression (aOR, 3.3; 95% CI, 1.5-7.6).

Study details: The data come from the Korean Sleep-Headache Study, a population-based, cross-sectional survey on headache and sleep involving 2,501 participants.

Disclosures: This study was supported by the National Research Foundation of Korea grant from the Korean government. S‐J Cho and M K Chu were site investigators for a multicenter trial sponsored by Otsuka Korea, Eli Lilly and Co., and others. S-J Cho and MK Chu have worked as advisory members for Teva and have declared research support/lecture honoraria/grants from different sources. The other authors declared no conflicts of interest.

Source: Han SM et al. Sci Rep. 2021 Jan 28. doi: 10.1038/s41598-021-82080-z.

Key clinical point: The prevalence of cutaneous allodynia (CA) was comparable among patients with probable migraine (PM) and migraine. Anxiety, depression, and headache frequency/intensity were significant factors for CA in PM.

Major finding: Participants with PM (n=289) and migraine (n=125) showed a similar prevalence of CA (14.5% vs. 16.0%; P = .701). The factors significantly associated with CA in PM were moderate (adjusted odds ratio [aOR], 2.4; 95% confidence interval [CI], 1.1-5.4) and severe (aOR, 4.0; 95% CI, 1.1-13.9) headache intensity, anxiety (aOR, 5.2; 95% CI, 1.7-16.3), and depression (aOR, 3.3; 95% CI, 1.5-7.6).

Study details: The data come from the Korean Sleep-Headache Study, a population-based, cross-sectional survey on headache and sleep involving 2,501 participants.

Disclosures: This study was supported by the National Research Foundation of Korea grant from the Korean government. S‐J Cho and M K Chu were site investigators for a multicenter trial sponsored by Otsuka Korea, Eli Lilly and Co., and others. S-J Cho and MK Chu have worked as advisory members for Teva and have declared research support/lecture honoraria/grants from different sources. The other authors declared no conflicts of interest.

Source: Han SM et al. Sci Rep. 2021 Jan 28. doi: 10.1038/s41598-021-82080-z.